Shree Gobind Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.40 M
as on 07-12-2024
- Paid Up Capital ₹ 2.40 M
as on 07-12-2024
- Company Age 18 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.70 M
as on 07-12-2024
- Revenue -84.06%
(FY 2022)
- Profit -79.61%
(FY 2022)
- Ebitda 533.60%
(FY 2022)
- Net Worth 1.37%
(FY 2022)
- Total Assets -15.33%
(FY 2022)
About Shree Gobind Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.40 M and a paid-up capital of Rs 2.40 M.
The company currently has active open charges totaling ₹4.70 M.
Meenu Khaneja and Sagar Khaneja serve as directors at the Company.
- CIN/LLPIN
U24232DL2006PTC146275
- Company No.
146275
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Feb 2006
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Shree Gobind Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Meenu Khaneja  | Director | 14-Feb-2006 | Current |
| Sagar Khaneja | Director | 11-Dec-2017 | Current |
Financial Performance of Shree Gobind Pharmaceuticals.
Shree Gobind Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 84.06% decrease. The company also saw a substantial fall in profitability, with a 79.61% decrease in profit. The company's net worth moved up by a moderate rise of 1.37%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shree Gobind Pharmaceuticals?
In 2021, Shree Gobind Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Radicon Laboratories Limited.Active 17 years 10 monthsMeenu Khaneja and Sagar Khaneja are mutual person
- Shree Radhey Gobind Pharmaceuticals Private LimitedActive 12 years 4 days
Meenu Khaneja and Sagar Khaneja are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Vijaya Bank Creation Date: 28 Jan 2009 | ₹4.70 M | Open |
How Many Employees Work at Shree Gobind Pharmaceuticals?
Unlock and access historical data on people associated with Shree Gobind Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shree Gobind Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shree Gobind Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
